Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?
Lenz
Georg
G
Lymphoma Section, Department of Internal Medicine III, University Hospital Grosshadern, Munich, Germany. georg.lenz@med.uni-muenchen.de
Dreyling
Martin
M
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000008:administration & dosage; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D013792:Thalidomide